Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid fibrils

Authors

  • Lei Gu,

    1. Department of Neurology, Brain Research Institute, Molecular Biology Institute, University of California, Los Angeles, California, USA
    Search for more papers by this author
  • Zhefeng Guo

    Corresponding author
    • Department of Neurology, Brain Research Institute, Molecular Biology Institute, University of California, Los Angeles, California, USA
    Search for more papers by this author

Address correspondence and reprint requests to Zhefeng Guo, Department of Neurology, University of California, Los Angeles, 710 Westwood Plaza, Los Angeles, CA 90095, USA.

E-mail: zhefeng@ucla.edu

Abstract

Deposition of amyloid β (Aβ) in the brain is a pathological hallmark of Alzheimer's disease. There are two major isoforms of Aβ: the 42-residue Aβ42 and the 40-residue Aβ40. The only difference between Aβ42 and Aβ40 is that Aβ42 has two extra residues at the C-terminus. The amyloid plaques in Alzheimer's brains consist of mostly Aβ42 and some plaques contain only Aβ42, even though Aβ40 concentration is several-fold more than Aβ42. Using electron paramagnetic resonance, we studied the formation of amyloid fibrils using a mixture of Aβ42 and Aβ40 in vitro. We show that Aβ42 and Aβ40 form mixed fibrils in an interlaced manner, although Aβ40 is not as efficient as Aβ42 in terms of being incorporated into Aβ42 fibrils. Our results suggest that both Aβ42 and Aβ40 would be present in amyloid plaques if in vivo aggregation of Aβ were similar to the in vitro process. Therefore, there must be some mechanisms that lead to the preferential deposition of Aβ42 at the extracellular space. Identifying such mechanisms may open new avenues for therapeutic interventions to treat Alzheimer's disease.

Ancillary